

Clovis Oncology, Inc.  
Form 8-K  
January 13, 2014

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **January 13, 2014**

**Clovis Oncology, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**                      **001-35347**      **90-0475355**  
(State or other jurisdiction) (Commission (I.R.S. Employer  
of incorporation)              File Number) Identification No.)  
**2525 28<sup>th</sup> Street, Suite 100**

**Boulder, Colorado**              **80301**  
(Address of principal  
executive offices)              (Zip Code)

Registrant's telephone number, including area code: **(303) 625-5000**

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---



**Item 2.02 Results of Operations and Financial Condition**

Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2013, on January 13, 2014, Clovis Oncology, Inc. (the “Company”) issued a press release announcing that the Company had \$323 million in cash as of December 31, 2013 and expects a cash burn of approximately \$120 million for the year ending December 31, 2014. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 2.02 of Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2013 and its results of operations for the three months and year ended December 31, 2013. The audit of the Company’s consolidated financial statements for the year ended December 31, 2013 is ongoing and could result in changes to the information set forth above.

The information in this Item 2.02 of Form 8-K and the information incorporated by reference herein, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Number and Description

99.1 Press Release, dated January 13, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

January 13, 2014    By:    /s/ Erle T. Mast  
                                 Name: Erle T. Mast  
                                 Title: Executive Vice President and Chief Financial Officer

- 3 -

---

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, dated January 13, 2014.

- 4 -